Elevated levels of inflammatory markers in women with rheumatoid arthritis

Costa, Carlos Maurício de Castro; Santos, M. A. T.; Pernambuco, Andrei Pereira

doi:10.1080/15321819.2019.1649695

Cited by 5 publications

(2 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These laboratory tests are generally irrelevant to knee OA treatment, because most treatment decisions are based on clinical severity, rather than laboratory tests (25). Further, rheumatoid arthritis can have a variable course influenced by inflammatory mediators, whereas knee OA is reliably slow and steady (6,26).…”

Section: Discussionmentioning

confidence: 99%

Construction of an Administrative Osteoarthritis Severity Index

Gebauer

Chrusciel

Salas

et al. 2022

ACR Open Rheumatology

View full text Add to dashboard Cite

Objective Electronic health record (EHR) databases are a powerful resource to investigate clinical trajectories of osteoarthritis (OA). There are no existing EHR tools to evaluate risk for knee arthroplasty (KA). We developed an OA severity index (OASI) using EHR data and demonstrate the index's association with time to KA. Methods This retrospective cohort study used 2010‐2018 nationally distributed Optum EHR data. Eligible patients were 45 to 80 years old with a new diagnosis of knee OA in 2011‐2012 and no prior KA. The OASI was a sum of first instance of x‐ray imaging, advanced imaging, intra‐articular injection, nonsteroidal anti‐inflammatory drugs, and opioids. Principal components analysis index (PCI) score was also explored. Extended Cox proportional hazard models assessed time‐dependent OASI and time to KA. Results Among 16,675 eligible patients, 12.7% underwent KA. Median follow‐up time was 72 months. Adjusted OASI models showed each additional event almost doubled the risk for KA (adjusted hazard ratio = 1.80, 95% confidence interval: 1.75‐1.86). Similar results were observed for PCI. Conclusion The sum OASI performs well identifying patients who would undergo KA and offers simplicity versus the PCI. Although replication in other cohorts is recommended, the OASI appears to be a novel and valid means to measure clinical OA severity in research studies using large EHR‐based cohorts.

show abstract

Section: Discussionmentioning

confidence: 99%

Construction of an Administrative Osteoarthritis Severity Index

Gebauer

Chrusciel

Salas

et al. 2022

ACR Open Rheumatology

View full text Add to dashboard Cite

show abstract

“…A large amount of IL-17 was also manufactured in peripheral blood mononuclear cells (PBMC) ( Kim et al, 2005 ), and its concentration was higher than that in healthy people ( Chabaud et al, 1999 ; Ziolkowska et al, 2000 ; Li et al, 2013 ). Several studies have proven that the content of IL-17 in synovial tissue and serum is directly related to the degree of RA joint injury ( Kirkham et al, 2006 ; Schofield et al, 2016 ; Siloşi et al, 2016 ; Lee and Bae, 2017 ; Costa et al, 2019 ). The increase in IL-17 levels in serum, synovial fluid, and PBMC is related to the expression of C-reactive protein, erythrocyte sedimentation rate, and rheumatoid factor ( Roşu et al, 2012 ; El-Maghraby et al, 2019 ).…”

Section: Bone Destruction and Synovial Hyperplasia In Ra Are Mediated...mentioning

confidence: 99%

A Role of IL-17 in Rheumatoid Arthritis Patients Complicated With Atherosclerosis

Wang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is mainly caused by joint inflammation. RA significantly increases the probability of cardiovascular disease. Although the progress of RA has been well controlled recently, the mortality of patients with RA complicated with cardiovascular disease is 1.5–3 times higher than that of patients with RA alone. The number of people with atherosclerosis in patients with RA is much higher than that in the general population, and atherosclerotic lesions develop more rapidly in patients with RA, which has become one of the primary factors resulting in the death of patients with RA. The rapid development of atherosclerosis in RA is induced by inflammation-related factors. Recent studies have reported that the expression of IL-17 is significantly upregulated in patients with RA and atherosclerosis. Simultaneously, there is evidence that IL-17 can regulate the proliferation, migration, and apoptosis of vascular endothelial cells and vascular smooth muscle cells through various ways and promote the secretion of several cytokines leading to the occurrence and development of atherosclerosis. Presently, there is no clear prevention or treatment plan for atherosclerosis in patients with RA. Therefore, this paper explores the mechanism of IL-17 in RA complicated with atherosclerosis and shows the reasons for the high incidence of atherosclerosis in patients with RA. It is hoped that the occurrence and development of atherosclerosis in patients with RA can be diagnosed or prevented in time in the early stage of lesions, and the prevention and treatment of cardiovascular complications in patients with RA can be enhanced to reduce mortality.

show abstract